Von Willebrand factor facilitates MELD-independent risk stratification on the waiting list for liver transplantation.
Model of End-Stage Liver Disease (MELD) is used for clinical decision making and organ allocation for orthotopic liver transplantation (OLT) and was previously upgraded via inclusion of serum sodium concentrations (MELD-Na). However, MELD-Na may underestimate complications arising from portal hypertension or infection. Von Willebrand factor antigen (vWF-Ag) correlates with portal pressure and seems capable of predicting complications in cirrhotic patients. Accordingly, this study aimed to evaluate vWF-Ag as an adjunct surrogate marker for risk stratification on the waiting list for OLT. Hence, WF-Ag at time of listing was assessed in patients listed for OLT. Clinical characteristics, MELD-Na and mortality on the waiting list were recorded. Prediction of three-month waiting list survival was assessed by receiver operating characteristics and net reclassification improvement. Interestingly, patients dying within three months on the waiting list displayed elevated levels of vWF-Ag (p<0.001). MELD-Na and vWF-Ag were comparable and independent in their predictive potential for three-month mortality on the waiting list (AUC:vWF-Ag=0.739;MELD-Na=0.764). Importantly, a vWF-Ag cut-off at 413% identified patients at risk for death within three months of listing with a higher odds ratio (OR) than the previously published cut-off at MELD-Na of 20 points (vWF-Ag:OR=10.873, 95%-CI:3.160-36.084; MELD-Na:OR=7.594, 95%-CI:2.578-22.372; p<0.001, respectively). Ultimately, inclusion of vWF-Ag into the MELD-Na equation significantly improved prediction of three-month waiting list mortality (AUC:MELD-Na-vWF=0.804). CONCLUSIONS: A single measurement of vWF-Ag at listing for OLT predicts early mortality. Combining vWF-Ag levels with MELD-Na improves risk stratification and may help to prioritize organ allocation in order to decrease waiting list mortality.